- Home
- JLS vs SERA Comparison
JLS vs SERA Comparison
Compare JLS & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | SERA |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 90.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JLS | SERA |
|---|---|---|
| Price | $18.56 | $3.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.6K | ★ 34.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $217.92 |
| Revenue Next Year | N/A | $479.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $15.48 | $1.37 |
| 52 Week High | $17.97 | $9.13 |
Technical Indicators
Market Signals| Indicator | JLS | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 56.38 |
| Support Level | $18.48 | $3.20 |
| Resistance Level | $18.75 | $3.18 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 27.28 | 83.33 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.